SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

A roundup of the most newsworthy healthcare press releases from PR Newswire, including FDA approval for Aktiia's cuffless ...

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and ...

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and ...

The biopharmaceutical industry is growing rapidly as a result of significant advancements in biotechnology and drug ...

GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or refractory multiple myeloma in combination with bortezomib ...

New Jersey-based drugmaker Bristol Myers Squibb this month dedicated its first production facility in Indiana, a former north-side warehouse transformed with $160 million into a clean-room ...

Meanwhile, the European Union has given the green light to GSK for its blood cancer drug, Blenrep. This approval aims to treat relapsed or treatment-resistant cancer forms affecting blood plasma cells ...

Mersana Therapeutics Inc. (NASDAQ:MRSN) is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates/ADC for cancer patients with unmet needs.